Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 34
- Registration Number
- NCT01098071
Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- Other: No anti-inflammatory treatmentDrug: Other Cox-2 inhibitorsDrug: Other Non-selective NSAIDs
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 27381
- Registration Number
- NCT01077843
An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)
Completed
- Conditions
- Cancer
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1392
- Registration Number
- NCT01077830
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
Completed
- Conditions
- AdenocarcinomaEsophageal CancerSquamous Cell Carcinoma
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 684815
- Registration Number
- NCT01077817
Vytorin Reexamination Study (0653A-174)
Completed
- Conditions
- Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2089
- Registration Number
- NCT01070966
EZETROL® Re-examination Study (MK0653-175)(COMPLETED)
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 4467
- Registration Number
- NCT01070953
FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 880
- Registration Number
- NCT01065779
A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)
Phase 4
Completed
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 24
- Registration Number
- NCT01044056
Cozaar XQ Re-examination Study (MK-0954-349)
Completed
- Conditions
- Hypertension
- Interventions
- Drug: amlodipine/losartan
- First Posted Date
- 2010-01-01
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 669
- Registration Number
- NCT01041807
Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)
Phase 3
Withdrawn
- Conditions
- Asthma
- Interventions
- Drug: SCH 32088 mometasone furoate (MF) metered-dose inhalerDrug: Placebo metered-dose inhaler BID
- First Posted Date
- 2009-12-07
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01026870